Literature DB >> 12524406

Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon.

P Seksik1, L Rigottier-Gois, G Gramet, M Sutren, P Pochart, P Marteau, R Jian, J Doré.   

Abstract

BACKGROUND AND AIMS: The colonic microflora is involved in the pathogenesis of Crohn's disease (CD) but less than 30% of the microflora can be cultured. We investigated potential differences in the faecal microflora between patients with colonic CD in remission (n=9), patients with active colonic CD (n=8), and healthy volunteers (n=16) using culture independent techniques.
METHODS: Quantitative dot blot hybridisation with six radiolabelled 16S ribosomal ribonucleic acid (rRNA) targeting oligonucleotide probes was used to measure the proportions of rRNA corresponding to each phylogenetic group. Temporal temperature gradient gel electrophoresis (TTGE) of 16S rDNA was used to evaluate dominant species diversity.
RESULTS: Enterobacteria were significantly increased in active and quiescent CD. Probe additivity was significantly lower in patients (65 (11)% and 69 (6)% in active CD and quiescent CD) than in healthy controls (99 (7)%). TTGE profiles varied markedly between active and quiescent CD but were stable in healthy conditions.
CONCLUSION: The biodiversity of the microflora remains high in patients with CD. Enterobacteria were observed significantly more frequently in CD than in health, and more than 30% of the dominant flora belonged to yet undefined phylogenetic groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524406      PMCID: PMC1774977          DOI: 10.1136/gut.52.2.237

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization.

Authors:  A Sghir; G Gramet; A Suau; V Rochet; P Pochart; J Dore
Journal:  Appl Environ Microbiol       Date:  2000-05       Impact factor: 4.792

2.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

3.  Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

Authors:  K L Madsen; J S Doyle; L D Jewell; M M Tavernini; R N Fedorak
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

Review 4.  Protection from gastrointestinal diseases with the use of probiotics.

Authors:  P R Marteau; M de Vrese; C J Cellier; J Schrezenmeir
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

5.  Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut.

Authors:  A Suau; R Bonnet; M Sutren; J J Godon; G R Gibson; M D Collins; J Doré
Journal:  Appl Environ Microbiol       Date:  1999-11       Impact factor: 4.792

6.  Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice.

Authors:  L O'Mahony; M Feeney; S O'Halloran; L Murphy; B Kiely; J Fitzgibbon; G Lee; G O'Sullivan; F Shanahan; J K Collins
Journal:  Aliment Pharmacol Ther       Date:  2001-08       Impact factor: 8.171

7.  Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study.

Authors:  P Gupta; H Andrew; B S Kirschner; S Guandalini
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-10       Impact factor: 2.839

8.  Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Authors:  M Guslandi; G Mezzi; M Sorghi; P A Testoni
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

9.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Authors:  B J Rembacken; A M Snelling; P M Hawkey; D M Chalmers; A T Axon
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

Review 10.  Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.

Authors:  F Shanahan
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

View more
  226 in total

1.  Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India.

Authors:  Ravi Verma; Anil Kumar Verma; Vineet Ahuja; Jaishree Paul
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

2.  Elevated lipopolysaccharide in the colon evokes intestinal inflammation, aggravated in immune modulator-impaired mice.

Authors:  Eunok Im; Franz Martin Riegler; Charalabos Pothoulakis; Sang Hoon Rhee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-21       Impact factor: 4.052

Review 3.  Nitrate, nitrite and nitric oxide reductases: from the last universal common ancestor to modern bacterial pathogens.

Authors:  Andrés Vázquez-Torres; Andreas J Bäumler
Journal:  Curr Opin Microbiol       Date:  2015-09-29       Impact factor: 7.934

4.  The bacterial pathogenesis and treatment of pouchitis.

Authors:  S D McLaughlin; S K Clark; P P Tekkis; R J Nicholls; P J Ciclitira
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

Review 5.  Crohn's disease and infections: a complex relationship.

Authors:  Gert De Hertogh; Karel Geboes
Journal:  MedGenMed       Date:  2004-08-10

6.  Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge.

Authors:  M F De La Cochetière; T Durand; P Lepage; A Bourreille; J P Galmiche; J Doré
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 7.  Why related bacterial species bloom simultaneously in the gut: principles underlying the 'Like will to like' concept.

Authors:  Sebastian E Winter; Andreas J Bäumler
Journal:  Cell Microbiol       Date:  2013-12-16       Impact factor: 3.715

8.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Comparative diversity analysis of gut microbiota in two different human flora-associated mouse strains.

Authors:  Xiaojing Zhang; Benhua Zeng; Zhiwei Liu; Zhenlin Liao; Wenxai Li; Hong Wei; Xiang Fang
Journal:  Curr Microbiol       Date:  2014-05-08       Impact factor: 2.188

10.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease.

Authors:  S J Ott; M Musfeldt; D F Wenderoth; J Hampe; O Brant; U R Fölsch; K N Timmis; S Schreiber
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.